Use of Diagnostic Algorithms for *NTRK* Fusion-Positive Tumors in Pathology Institutes in Switzerland
In May 2020, larotrectinib (Vitrakvi^®^) was approved as the first tumor-agnostic agent in Switzerland for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (*NTRK*) gene fusion. While in certain types of tumors an *NTRK* gene fusion is...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2021-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2021.07.030 |
| _version_ | 1826936711101284352 |
|---|---|
| author | Holger Moch Gieri Cathomas Milo Frattini Wolfram Jochum Erik Vassella Laurence de Leval Joachim Diebold Christian Britschgi Thomas McKee Lukas Bubendorf |
| author_facet | Holger Moch Gieri Cathomas Milo Frattini Wolfram Jochum Erik Vassella Laurence de Leval Joachim Diebold Christian Britschgi Thomas McKee Lukas Bubendorf |
| author_sort | Holger Moch |
| collection | DOAJ |
| description | In May 2020, larotrectinib (Vitrakvi^®^) was approved as the first tumor-agnostic agent in Switzerland for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (*NTRK*) gene fusion. While in certain types of tumors an *NTRK* gene fusion is often detectable, it is rare in some other types. As the detection of *NTRK* gene fusion opens up new treatment options for patients, it is vital to ensure that the detection methods and diagnostic algorithms in pathology institutes are optimized and of high quality. Detection can be performed by immunohistochemistry, next-generation sequencing or by fluorescence *in situ* hybridization. This review will discuss diagnostic algorithms based on underlying pathology that can be recommended for the detection of *NTRK* gene fusions in Switzerland. |
| first_indexed | 2024-04-24T23:19:21Z |
| format | Article |
| id | doaj.art-3ecf4984e517446aa26f4709383a3960 |
| institution | Directory Open Access Journal |
| issn | 2673-2106 |
| language | English |
| last_indexed | 2025-02-17T18:26:19Z |
| publishDate | 2021-03-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj.art-3ecf4984e517446aa26f4709383a39602024-12-12T17:11:17ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-21062021-03-0171Use of Diagnostic Algorithms for *NTRK* Fusion-Positive Tumors in Pathology Institutes in SwitzerlandHolger MochGieri CathomasMilo FrattiniWolfram JochumErik VassellaLaurence de LevalJoachim DieboldChristian BritschgiThomas McKeeLukas BubendorfIn May 2020, larotrectinib (Vitrakvi^®^) was approved as the first tumor-agnostic agent in Switzerland for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (*NTRK*) gene fusion. While in certain types of tumors an *NTRK* gene fusion is often detectable, it is rare in some other types. As the detection of *NTRK* gene fusion opens up new treatment options for patients, it is vital to ensure that the detection methods and diagnostic algorithms in pathology institutes are optimized and of high quality. Detection can be performed by immunohistochemistry, next-generation sequencing or by fluorescence *in situ* hybridization. This review will discuss diagnostic algorithms based on underlying pathology that can be recommended for the detection of *NTRK* gene fusions in Switzerland.https://doi.org/10.36000/hbT.OH.2021.07.030 |
| spellingShingle | Holger Moch Gieri Cathomas Milo Frattini Wolfram Jochum Erik Vassella Laurence de Leval Joachim Diebold Christian Britschgi Thomas McKee Lukas Bubendorf Use of Diagnostic Algorithms for *NTRK* Fusion-Positive Tumors in Pathology Institutes in Switzerland healthbook TIMES. Oncology Hematology |
| title | Use of Diagnostic Algorithms for *NTRK* Fusion-Positive Tumors in Pathology Institutes in Switzerland |
| title_full | Use of Diagnostic Algorithms for *NTRK* Fusion-Positive Tumors in Pathology Institutes in Switzerland |
| title_fullStr | Use of Diagnostic Algorithms for *NTRK* Fusion-Positive Tumors in Pathology Institutes in Switzerland |
| title_full_unstemmed | Use of Diagnostic Algorithms for *NTRK* Fusion-Positive Tumors in Pathology Institutes in Switzerland |
| title_short | Use of Diagnostic Algorithms for *NTRK* Fusion-Positive Tumors in Pathology Institutes in Switzerland |
| title_sort | use of diagnostic algorithms for ntrk fusion positive tumors in pathology institutes in switzerland |
| url | https://doi.org/10.36000/hbT.OH.2021.07.030 |
| work_keys_str_mv | AT holgermoch useofdiagnosticalgorithmsforntrkfusionpositivetumorsinpathologyinstitutesinswitzerland AT giericathomas useofdiagnosticalgorithmsforntrkfusionpositivetumorsinpathologyinstitutesinswitzerland AT milofrattini useofdiagnosticalgorithmsforntrkfusionpositivetumorsinpathologyinstitutesinswitzerland AT wolframjochum useofdiagnosticalgorithmsforntrkfusionpositivetumorsinpathologyinstitutesinswitzerland AT erikvassella useofdiagnosticalgorithmsforntrkfusionpositivetumorsinpathologyinstitutesinswitzerland AT laurencedeleval useofdiagnosticalgorithmsforntrkfusionpositivetumorsinpathologyinstitutesinswitzerland AT joachimdiebold useofdiagnosticalgorithmsforntrkfusionpositivetumorsinpathologyinstitutesinswitzerland AT christianbritschgi useofdiagnosticalgorithmsforntrkfusionpositivetumorsinpathologyinstitutesinswitzerland AT thomasmckee useofdiagnosticalgorithmsforntrkfusionpositivetumorsinpathologyinstitutesinswitzerland AT lukasbubendorf useofdiagnosticalgorithmsforntrkfusionpositivetumorsinpathologyinstitutesinswitzerland |